How Much Upside is Left in Halozyme Therapeutics (HALO)? Wall Street Analysts Think 27.08%

Shares of Halozyme Therapeutics (HALO) have gained 5.2% over the past four weeks to close the last trading session at $48, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of$61 indicates a potential upside of 27.1%.The mean estimate comprises 10 short-term price targets with a standard deviation of $7.94. While the lowest estimate of$49 indicates a 2.1% increase from the current ...